Ignite Creation Date:
2025-12-24 @ 7:08 PM
Ignite Modification Date:
2026-01-01 @ 7:11 PM
Study NCT ID:
NCT06324357
Status:
RECRUITING
Last Update Posted:
2025-12-22
First Post:
2024-03-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Sponsor:
Boehringer Ingelheim
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-06-03
Start Date Type:
ACTUAL
Primary Completion Date:
2029-01-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-01-08
Completion Date Type:
ESTIMATED
First Submit Date:
2024-03-15
First Submit QC Date:
None
Study First Post Date:
2024-03-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-19
Last Update Post Date:
2025-12-22
Last Update Post Date Type:
ESTIMATED